Search Results - "Muijlwijk, Tara"

The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites by Wondergem, Niels E., Nauta, Irene H., Muijlwijk, Tara, Leemans, C. René, van de Ven, Rieneke

“…Purpose To understand why some patients respond to immunotherapy but many do not, a clear picture of the tumor microenvironment (TME) of head and neck squamous…”
Get full text

Hallmarks of a genomically distinct subclass of head and neck cancer by Muijlwijk, Tara, Nauta, Irene H., van der Lee, Anabel, Grünewald, Kari J. T., Brink, Arjen, Ganzevles, Sonja H., Baatenburg de Jong, Robert J., Atanesyan, Lilit, Savola, Suvi, van de Wiel, Mark A., Peferoen, Laura A. N., Bloemena, Elisabeth, van de Ven, Rieneke, Leemans, C. René, Poell, Jos B., Brakenhoff, Ruud H.

“…Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs). Besides mutations, these copy number changes are key…”
Get full text

Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites by Muijlwijk, Tara, Nijenhuis, Dennis N L M, Ganzevles, Sonja H, Brink, Arjen, Ke, Changlin, Fass, Joseph N, Rajamanickam, Venkatesh, Leemans, C René, Koguchi, Yoshinobu, Fox, Bernard A, Poell, Jos B, Brakenhoff, Ruud H, van de Ven, Rieneke

“…BackgroundThe response rate to immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) receptor is 13%–18% for patients with recurrent or…”
Get full text

Immune cell topography of head and neck cancer by Muijlwijk, Tara, Nijenhuis, Dennis N L M, Ganzevles, Sonja H, Ekhlas, Fatima, Ballesteros-Merino, Carmen, Peferoen, Laura A N, Bloemena, Elisabeth, Fox, Bernard A, Poell, Jos B, Leemans, C René, Brakenhoff, Ruud H, van de Ven, Rieneke

“…BackgroundApproximately 50% of head and neck squamous cell carcinomas (HNSCC) recur after treatment with curative intent. Immune checkpoint inhibitors are…”
Get full text

935 Attraction of immune cells by head and neck cancer cell lines and primary tumor-conditioned supernatants by Muijlwijk, Tara, Remkes, Naomi, Poell, Jos, Leemans, René, Brakenhoff, Ruud, Ven, Rieneke van de

“…BackgroundHead and neck squamous cell carcinomas (HNSCC) are classified in human papillomavirus (HPV)-positive and HPV-negative tumors. In general,…”
Get full text

940 High plasma cell presence in oral cancers with high frequencies of tumor-infiltrating B cells identified by transcriptional, flow cytometric and spatial profiling by Nijenhuis, Dennis NLM, Muijlwijk, Tara, Ganzevles, Sonja H, Hansson, Stina Lie, Lee, Anabel van der, Nauta, Irene, Rene Leemans, C, Brakenhoff, Ruud H, Ven, Rieneke van de

“…BackgroundImmune Checkpoint Inhibitors (ICI) are approved for the treatment of recurrent or metastatic Head and Neck Squamous Cell Carcinomas (HNSCC), but are…”
Get full text

1487 PD-1 expression on tumor-infiltrating T-lymphocytes as determinant of the head and neck cancer tumor immune microenvironment rather than anatomical site by Muijlwijk, Tara, Nijenhuis, Dennis NLM, Ganzevles, Sonja H, Brink, Arjen, Ke, Changlin, Fass, Joseph N, Rajamanickam, Venkatesh, Rene Leemans, C, Koguchi, Yoshinobu, Fox, Bernard A, Poell, Jos B, Brakenhoff, Ruud H, Ven, Rieneke van de

“…BackgroundThe response rate to immune checkpoint inhibitors (ICI) targeting programmed cell death 1 (PD-1) receptor is 13–18% for patients with recurrent or…”
Get full text

Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8 + T Cells by Drijvers, Jefte M, Gillis, Jacob E, Muijlwijk, Tara, Nguyen, Thao H, Gaudiano, Emily F, Harris, Isaac S, LaFleur, Martin W, Ringel, Alison E, Yao, Cong-Hui, Kurmi, Kiran, Juneja, Vikram R, Trombley, Justin D, Haigis, Marcia C, Sharpe, Arlene H

“…Metabolic constraints in the tumor microenvironment constitute a barrier to effective antitumor immunity and similarities in the metabolic properties of T…”
Get more information

Secretome and immune cell attraction analysis of head and neck cancers by Muijlwijk, Tara, Wondergem, Niels E., Ekhlas, Fatima, Remkes, Naomi, Nijenhuis, Dennis N. L. M., Fritz, Lennart, Ganzevles, Sonja H., Miedema, Iris H. C., Leemans, C. René, Poell, Jos B., Brakenhoff, Ruud H., van de Ven, Rieneke

“…Immune checkpoint inhibitors are approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) but the response rate is only 13–18%. For an…”
Get full text